Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Armuzzi

Showing results (181-190 of 320) with videos related to

Pageof 32
Sort By:
Inflammatory Bowel Diseases|July 2, 2014
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitisAlessandro Armuzzi, Daniela Pugliese, Silvio Danese, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 17, 2010
The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel diseaseAmbrogio Orlando, Alessandro Armuzzi, Claudio Papi, et al.
Inflammatory Bowel Diseases|July 29, 2020
The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical ImplicationsFranco Scaldaferri, Gianluca Ianiro, Giuseppe Privitera, et al.
Journal of Crohn'S & Colitis|June 18, 2026
Virtual chromoendoscopy with linked color imaging versus dye-chromoendoscopy in the surveillance of patients with long-standing colonic inflammatory bowel diseaseRoberto Gabbiadini, Gianluca Franchellucci, Francesco Minini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 26, 2018
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective studyAnna Viola, Daniela Pugliese, Sara Renna, et al.
Journal of Clinical Medicine|November 27, 2025
Sessile Serrated Lesions in Inflammatory Bowel Disease: Hidden Players in Colitis-Associated Colorectal Cancer?Roberto de Sire, Diletta De Deo, Miriana Mercurio, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 12, 2019
Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative ColitisBruce E Sands, Pam R Taub, Alessandro Armuzzi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 28, 2019
Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn's diseaseAlessandro Armuzzi, Gabriele Riegler, Federica Furfaro, et al.
Journal of Crohn'S & Colitis|November 1, 2024
Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY StudiesRaja Atreya, Marc Ferrante, Remo Panaccione, et al.
Journal of Crohn'S & Colitis|December 27, 2025
Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC studyGiuseppe Privitera, Cristina Bezzio, Arianna Dal Buono, et al.
Pageof 32

Showing results (181-190 of 320) with videos related to

Sort By:
Pageof 32
Inflammatory Bowel Diseases|July 2, 2014
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitisAlessandro Armuzzi, Daniela Pugliese, Silvio Danese, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 17, 2010
The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel diseaseAmbrogio Orlando, Alessandro Armuzzi, Claudio Papi, et al.
Inflammatory Bowel Diseases|July 29, 2020
The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical ImplicationsFranco Scaldaferri, Gianluca Ianiro, Giuseppe Privitera, et al.
Journal of Crohn'S & Colitis|June 18, 2026
Virtual chromoendoscopy with linked color imaging versus dye-chromoendoscopy in the surveillance of patients with long-standing colonic inflammatory bowel diseaseRoberto Gabbiadini, Gianluca Franchellucci, Francesco Minini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 26, 2018
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective studyAnna Viola, Daniela Pugliese, Sara Renna, et al.
Journal of Clinical Medicine|November 27, 2025
Sessile Serrated Lesions in Inflammatory Bowel Disease: Hidden Players in Colitis-Associated Colorectal Cancer?Roberto de Sire, Diletta De Deo, Miriana Mercurio, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 12, 2019
Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative ColitisBruce E Sands, Pam R Taub, Alessandro Armuzzi, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 28, 2019
Epidemiological features and disease-related concerns of a large cohort of Italian patients with active Crohn's diseaseAlessandro Armuzzi, Gabriele Riegler, Federica Furfaro, et al.
Journal of Crohn'S & Colitis|November 1, 2024
Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY StudiesRaja Atreya, Marc Ferrante, Remo Panaccione, et al.
Journal of Crohn'S & Colitis|December 27, 2025
Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC studyGiuseppe Privitera, Cristina Bezzio, Arianna Dal Buono, et al.
Pageof 32